All News

Article

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA

MedPage Today Mar 23, 2023

Tofacitinib (Xeljanz) in patients with rheumatoid arthritis (RA) stood out among several other biologic and targeted synthetic disease-modifying antirheumatic drugs (sDMARDs) when it came to the incidence of interstitial lung disease (ILD), a retrospective cohort study showed.

Article

What to do about pre-clinical RA?

Robert Chao, MD Mar 20, 2023

RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, and in particular, what to do regarding pre-clinical RA.

30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj

https://bit.ly/3ZspPdH

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E

https://bit.ly/42TKNVU

Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM

https://bit.ly/3ziEZHV

https://bit.ly/3M35Jnl

https://bit.ly/3Zm4Jxw

What to do about pre-clinical RA? Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA. https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi

https://bit.ly/40w6JVH

#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056

https://bit.ly/3JK6nn8

Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW

https://bit.ly/40sbhfe

Biosimilars are coming! Multiple adalimumab biosimilars this year - will we see a dramatic price difference? @RheumNow #RNL2023 https://t.co/8vdtXtEGOO

Will be begin using sputum instead of blood serologies to detect RA? - sputum seropositive CCP may be associated with development of clinical RA - 4 fold higher risk if (induced) sputum CCP+ @RheumNow #RNL2023 https://t.co/Z85GDwIyl8

#RNL2023 Year in Review Sputum antibody predicts future development of RA Hazard ratio 4.2 if any sputum antibody positive (CCP IgG/IgA, RF IgM and IgA) Strongest association with CCP IgA Supports pre-RA as mucosal disease @RheumNow https://t.co/Js4JPZiLDB

Smoking *may* only ⬆️ risk of #RA if shared epitope present AND double positive By @Janetbirdope #RNL2023 https://t.co/TG1hseVCsD

Could MTX every other week dosing be an option in patients with stable disease..? #RNL2023 https://t.co/EZRdQnuXjy

Long live the GOAT Rx: MTX 🐐🐐 History of usage dating back to 1950 Use 1st-line Optimize dose Supplement folic acid Split dose Give SQ Use in combination therapy Dr Joel Kremer #RNL2023 @RheumNow https://t.co/CCBvQoNHXo

#ClinicalPearl #Methotrexate weekly May reduce side effects in rapidly dividing cells vs using it daily or every few days. GI, oral, bone marrow side effects should be less if once a week. Joel Kremer ⁦@RheumNow⁩ #RNL2023 https://t.co/i0LZoQuK0w

How is a biosimilar approved? Comparative effectiveness study for the reason that the medication was initial approved required, not for other indications Jonathan Kay shows ex of ETN-ykro vs reference ETN in RA Non-inferior in immunogenicity, safety, efficacy @RheumNow #RNL2023 https://t.co/OOHie9Qr5t

Was amazed at the tons of biosimilar TNF options @_connectedcare uses in Australia... coming soon to the US! Jonathan Kay #RNL2022 shows the lists of biosimilar May be w/in batch-to-batch variability, unintended drift, or deliberate process changes (evolution) @RheumNow https://t.co/sfVQspxbyr

Jonathan Kay on #RNL2023: Biosimilar is well-researched with cost savings These savings should benefit the patients Incentives for physicians as well in form of decreased prior auth burdens @RheumNow

Topics

All News

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA

What to do about pre-clinical RA?

Do you get our email newsletter?